EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Cordlife GrouCordlife Group (CLIFF) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of Cordlife GrouCordlife Group $0.15, price $0.15, upside -0.3%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN SG2E64980112

CG Cordlife GrouCordlife Group logo Thin data Sep 24, 2026

Cordlife GrouCordlife Group

CLIFF · US

Low PriorityFair Value upside is limited and quality is weak.

·Fair value $0.1500 · Fairly valued (−0.3%)
!Quality 46/100
!Weak Growth (revenue 5y −8.0 %/yr)
!Loss-making · -33.3% net margin (TTM)
!High debt · negative free cash flow
!Narrow moat 6/100
!Evidence only low, so the estimate is less certain

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$1.07 $0.0689 Fair Value $0.1500 Aug 2015 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $0.0689 – $1.07 · fair‑value band $0.1200 – $0.2300 · the $0.1505 price screens above the $0.1500 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cordlife GrouCordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. It operates in two segments, Banking and Diagnostics.

Show more

Cordlife GrouCordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. It operates in two segments, Banking and Diagnostics. The Banking segment collects, processes, banks, and tests biological materials, such as cord blood, lining, and tissue samples. The Diagnostics segment offers diagnostic testing services, such as newborn genetic and metabolic screenings; pediatric vision and ear screenings; pediatric allergen test; and genetic talent test services. The company also provides corneal lenticule banking, and lifestyle genetic screening services for adults. In addition, it offers life sprouts, medical laboratory, marketing, and property investment services, as well as medical and pharmaceutical research and development and consulting services. Cordlife Group Limited was incorporated in 2001 and is based in Singapore.

Stock analysis

Cordlife GrouCordlife Group (CLIFF) currently trades at $0.1505, while our model-based Fair Value estimate is $0.1500, so the stock looks roughly fairly valued today (gap 0.3%).

Show more

Valuation

How firm this estimate is: it rests on 3 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.1200 (bear) to $0.2300 (bull), the price of $0.1505 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Cordlife GrouCordlife Group reported revenue of 38.8M SGD in FY2025 versus 56.7M SGD in FY2021, a compound −9.0%/yr. Reported net income was −12.6M SGD in FY2025.

Key figures

Market cap $38.6M · P/S ratio 1.01 · EPS (TTM) $−0.0400 · Net margin −32.5% · Return on equity −11.5% · Return on assets (EBIT) −2.0% · Operating margin −25.1% · Revenue (TTM) 38.3M SGD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades at its 52-week high and 118% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at 0%, CLIFF screens cheaper than that median.

Fair Value models

Bear $0.1200 Fair Value $0.1500 Bull $0.2300
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.1600 $0.2100 $0.3200 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.1600 $0.2100 $0.3200 54

Open the full fair value analysis →

Notify me when CLIFF reaches fair value

Put CLIFF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 46/100

Of which business quality 43 · Market factors (momentum, volatility) 59

Profitability 5
Margins and returns on capital today
Quality Growth 91
Are margins and returns improving?
Cashflow 10
Earnings quality: real cash, not paper profit
Fin. Strength 25
Balance sheet, leverage, solvency risk
Investment 98
Disciplined investing over empire-building
Low Volatility 45
Calm price path (market factor)
Momentum 73
Price trend over the last 3–12 months (market factor)
52W Momentum 49
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+39.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.0%
Start year 2020 (pandemic). Over 10 years: −4.2% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
11.9% (2020) → −38.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch CLIFF, get fair value alerts →

Compare Cordlife GrouCordlife Group with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $675.05 $686.04 +2%
Danaher Corporation DHR $221.55 $209.18 −6%
WuXi AppTec Co 603259 ¥162.40 ¥178.64 +10%
Agilent Technologies, Inc A $175.03 $64.17 −63%
Lonza Group LONN CHF 565.60 CHF 151.69 −73%
IQVIA Holdings IQV $270.37 $297.41 +10%
Waters Corporation WAT $433.54 $106.46 −75%
Illumina, Inc ILMN $271.90 $295.60 +9%
IDEXX Laboratories, Inc IDXX $533.44 $495.84 −7%
Mettler-Toledo International Inc MTD $1,512 $644.24 −57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cordlife GrouCordlife Group · Fair Value
$0.1500 −0%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Cordlife GrouCordlife Group Fair Value". https://www.fairvalue-calculator.com/stock/CLIFF

Frequently asked questions

Is Cordlife GrouCordlife Group (CLIFF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.1500 versus the last price from Sep 25, 2026 of $0.1505, about −0% upside (fairly valued).
What is the fair value of CLIFF?
Our model-based fair value for Cordlife GrouCordlife Group is $0.1500 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.1505.
What is the quality score of CLIFF?
Cordlife GrouCordlife Group has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cordlife GrouCordlife Group (CLIFF)?
Our model-based price target is the fair value of $0.1500 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $0.1200, optimistic scenario $0.2300. It is a calculation from audited fundamentals, not an analyst target.
What is the Cordlife GrouCordlife Group stock forecast for 2026?
Our models put fair value at $0.1500, about −0% upside versus the last price from Sep 25, 2026 of $0.1505 (fairly valued). Cautious scenario $0.1200, optimistic scenario $0.2300. The calculation is refreshed regularly with new filings.
What is the revenue of Cordlife GrouCordlife Group (CLIFF)?
Cordlife GrouCordlife Group reported trailing-twelve-month revenue of about 38.3M SGD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Cordlife GrouCordlife Group (CLIFF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cordlife GrouCordlife Group it is $0.1500 per share (as of Sep 24, 2026), against a price of $0.1505. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Cordlife GrouCordlife Group stock overvalued or undervalued in 2026?
As of Sep 24, 2026, CLIFF trades above its calculated fair value: price $0.1505, fair value $0.1500, a gap of about −0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CLIFF?
No. The price is what the market pays today ($0.1505); the fair value is what the company's own numbers justify ($0.1500). For Cordlife GrouCordlife Group the two are $0.0005 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cordlife GrouCordlife Group worth?
The market values Cordlife GrouCordlife Group at about $38.6M (market capitalisation, as of Sep 24, 2026). Per share that is $0.1505; our models calculate a fair value of $0.1500 per share.
What do the bullish and bearish scenarios say about CLIFF?
Our models span a range for Cordlife GrouCordlife Group: cautious scenario $0.1200, base $0.1500, optimistic $0.2300 per share (as of Sep 24, 2026, price $0.1505). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is CLIFF from its 52-week high?
Cordlife GrouCordlife Group trades at $0.1505, at its 52-week high of $0.1505 and 118% above the low of $0.0689 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1500 is for.
Which stocks are comparable to Cordlife GrouCordlife Group?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cordlife GrouCordlife Group stock attractive at the current price?
The data as of Sep 24, 2026: price $0.1505, calculated fair value $0.1500 (−0%), Quality Score 46/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CLIFF calculated?
We run Cordlife GrouCordlife Group through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.1500, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Cordlife GrouCordlife Group itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cordlife GrouCordlife Group (CLIFF)?
The latest price we hold is from Sep 25, 2026 and stands at $0.1505. Our model-based fair value is $0.1500, about −0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cordlife GrouCordlife Group right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($0.1200 to $0.2300) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Cordlife GrouCordlife Group

How large is the market capitalisation of Cordlife GrouCordlife Group (CLIFF)?
The market capitalisation of Cordlife GrouCordlife Group is $38.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cordlife GrouCordlife Group (CLIFF)?
The price-to-sales ratio of Cordlife GrouCordlife Group is 1.01 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cordlife GrouCordlife Group (CLIFF)?
Earnings per share at Cordlife GrouCordlife Group are $−0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Cordlife GrouCordlife Group (CLIFF)?
The net margin of Cordlife GrouCordlife Group is −32.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cordlife GrouCordlife Group (CLIFF)?
The return on equity (ROE) of Cordlife GrouCordlife Group is −11.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cordlife GrouCordlife Group (CLIFF)?
On an EBIT basis the return on assets of Cordlife GrouCordlife Group is −2.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cordlife GrouCordlife Group (CLIFF)?
The operating margin of Cordlife GrouCordlife Group is −25.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cordlife GrouCordlife Group (CLIFF)?
Revenue at Cordlife GrouCordlife Group is growing −6.1% versus a year earlier (3y avg −11.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cordlife GrouCordlife Group (CLIFF)?
Earnings per share at Cordlife GrouCordlife Group are growing −57.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Cordlife GrouCordlife Group (CLIFF) generate?
The free cash flow of Cordlife GrouCordlife Group is −728K SGD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Cordlife GrouCordlife Group (CLIFF) hold?
Cordlife GrouCordlife Group holds more cash than debt, 13.5M SGD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.